Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23124238 | 0.99 | SIGMAR1 (0.37) | SIGMAR1SLC18A3GBA1TSHRHTT | |
| SCHEMBL23139690 | 0.77 | SIGMAR1 (0.40) | SIGMAR1SLC18A3 | |
| SCHEMBL24700601 | 0.77 | KCNH2 (0.44) | — | |
| Hydrochloric Acid SCHEMBL23123346 | 0.76 | KCNH2 (0.45) | — | |
| SCHEMBL248803 | 0.71 | TDP1 (0.51) | SIGMAR1SLC18A3TSHRHTT | |
| SCHEMBL23139662 | 0.69 | ALPL (0.31) | — | |
| Hydrochloric Acid SCHEMBL23123283 | 0.67 | ALPL (0.31) | — | |
| SCHEMBL9850474 | 0.67 | SLC18A3 (0.54) | SIGMAR1SLC18A3 | |
| SCHEMBL23124014 | 0.67 | HRH3 (0.43) | SIGMAR1TSHRHTTHRH3 | |
| SCHEMBL11766707 | 0.61 | ALDH1A1 (0.36) | SIGMAR1TSHRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | SIGMAR1 1641/4885SLC18A3 2438/4885GBA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.